Subacute Sclerosing Panencephalitis (SSPE), a rare and usually fatal neurodegenerative disease in children, has come under judicial scrutiny after a petition sought a state response for treatment support, research, and financial aid. The matter has brought into light the absence of a dedicated policy in Maharashtra for managing the disease and supporting affected families.
What is SSPE?
SSPE is a slow, persistent viral infection linked to measles. It develops when the mutated measles virus remains in the central nervous system and gradually damages the brain. The disease causes progressive neurological decline in children. Common effects include:
- Loss of vision and movement.
- Difficulty in eating and swallowing.
- Muscular rigidity.
- Seizures and worsening cognitive decline.
- Coma and death in advanced stages.
Public Interest Litigation and Relief Sought
The petition before the Bombay High Court seeks directions to the state to frame a policy for SSPE. It also asks for a research programme to find a cure and for financial assistance to families of affected children. The plea argues that the disease has no known cure and only symptomatic treatment is possible at present. The petition further states that treatment costs are high and often run into lakhs of rupees. It claims that SSPE is not covered under many health insurance policies, leaving families under severe financial stress.
Public Health and Measles Link
SSPE is directly linked to measles infection, making measles control crucial for prevention. The issue gains importance as India continues to work towards measles elimination, with the target now extended to 2026. The petition notes concern that cases of SSPE, particularly in Maharashtra, are rising despite vaccination efforts. The case also raises questions about:
- Long-term surveillance of measles complications.
- Awareness among parents and health workers.
- Support systems for families of children with rare diseases.
Judicial Review and Policy Gap
The High Court is expected to examine whether the state has a duty to formulate a policy for rare paediatric diseases like SSPE. The case brings attention to gaps in rare disease management, public health preparedness, and financial protection for affected households.
Last Modified: April 27, 2026